AR077167A2 - Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos - Google Patents
Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicosInfo
- Publication number
- AR077167A2 AR077167A2 ARP100100844A ARP100100844A AR077167A2 AR 077167 A2 AR077167 A2 AR 077167A2 AR P100100844 A ARP100100844 A AR P100100844A AR P100100844 A ARP100100844 A AR P100100844A AR 077167 A2 AR077167 A2 AR 077167A2
- Authority
- AR
- Argentina
- Prior art keywords
- organic compounds
- particles
- allotropic organic
- solid state
- allotropic
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 5
- 239000002245 particle Substances 0.000 title abstract 4
- 238000002425 crystallisation Methods 0.000 title abstract 3
- 230000008025 crystallization Effects 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 239000012798 spherical particle Substances 0.000 abstract 2
- 229930182558 Sterol Natural products 0.000 abstract 1
- 239000012736 aqueous medium Substances 0.000 abstract 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001597 nifedipine Drugs 0.000 abstract 1
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 abstract 1
- 229960002698 oxatomide Drugs 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 150000003432 sterols Chemical class 0.000 abstract 1
- 235000003702 sterols Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Un método para realizar la cristalizacion en estado solido de partículas conformadas de compuestos orgánicos alotropicos, que comprende: a) crear una mezcla que consiste esencialmente en dos o más compuestos orgánicos alotropicos, en el que cada uno de los compuestos es de forma cristalina mixta, amorfa o tanto cristalina como amorfa; b) fabricar dicha mezcla en una pluralidad de partículas esféricas; c) exponer dichas partículas esféricas a una atmosfera que contiene vapores de uno o más disolventes para cada uno de dichos compuestos orgánicos alotropicos durante un tiempo suficiente para realizar una cristalizacion en estado solido de cada uno de dichos compuestos orgánicos alotropicos en su forma cristalina más estable; y d) recuperar dichas partículas; en el que las partículas recuperadas mantienen la forma esférica en el almacenamiento en medio acuoso durante por lo menos un mes. Reivindicacion 3: El método, de acuerdo con la reivindicacion 1, caracterizado porque dicho disolvente se selecciona del grupo que comprende: agua, etanol, acetona, ácido acético, tolueno, benceno y combinaciones de los mismos. Reivindicacion 4: El método, de acuerdo con la reivindicacion 3, caracterizado porque al menos uno de dichos compuestos orgánicos alotropicos es un esterol o esteroide. Reivindicacion 6: El método, de acuerdo con la reivindicacion 4, caracterizado porque dicha formulacion comprende colesterol y comprende además un compuesto orgánico alotropico seleccionado del grupo que comprende: astemizol, nifedipina y oxatomida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/030,388 US6287693B1 (en) | 1998-02-25 | 1998-02-25 | Stable shaped particles of crystalline organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077167A2 true AR077167A2 (es) | 2011-08-10 |
Family
ID=21853984
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100728A AR018107A1 (es) | 1998-02-25 | 1999-02-23 | Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo |
| ARP100100845A AR077168A2 (es) | 1998-02-25 | 2010-03-17 | Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida |
| ARP100100844A AR077167A2 (es) | 1998-02-25 | 2010-03-17 | Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100728A AR018107A1 (es) | 1998-02-25 | 1999-02-23 | Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo |
| ARP100100845A AR077168A2 (es) | 1998-02-25 | 2010-03-17 | Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida |
Country Status (34)
| Country | Link |
|---|---|
| US (7) | US6287693B1 (es) |
| EP (4) | EP1056444B1 (es) |
| JP (2) | JP4885357B2 (es) |
| KR (1) | KR100726315B1 (es) |
| CN (2) | CN1146407C (es) |
| AR (3) | AR018107A1 (es) |
| AT (2) | ATE345779T1 (es) |
| AU (1) | AU747779B2 (es) |
| BR (1) | BR9908156A (es) |
| CA (1) | CA2319176C (es) |
| CL (1) | CL2010001333A1 (es) |
| CY (1) | CY1118522T1 (es) |
| CZ (1) | CZ301042B6 (es) |
| DE (2) | DE69934099T2 (es) |
| DK (3) | DK2085075T3 (es) |
| EE (1) | EE05019B1 (es) |
| ES (3) | ES2609284T3 (es) |
| HU (1) | HUP0101271A3 (es) |
| ID (1) | ID26523A (es) |
| IL (2) | IL137970A0 (es) |
| MY (1) | MY138375A (es) |
| NO (1) | NO331804B1 (es) |
| NZ (1) | NZ505987A (es) |
| PE (1) | PE20000393A1 (es) |
| PL (1) | PL196369B1 (es) |
| PT (1) | PT2085075T (es) |
| RU (1) | RU2225708C2 (es) |
| SA (1) | SA99200098B1 (es) |
| TR (1) | TR200002462T2 (es) |
| TW (1) | TWI256308B (es) |
| UA (1) | UA73470C2 (es) |
| UY (1) | UY25404A1 (es) |
| WO (1) | WO1999043304A1 (es) |
| ZA (1) | ZA991058B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| CA2485834C (en) | 2002-05-16 | 2007-07-17 | Tibotec Pharmaceuticals Ltd. | Pseudopolymorphic forms of a hiv protease inhibitor |
| US20040028747A1 (en) * | 2002-08-06 | 2004-02-12 | Tucker Christopher J. | Crystalline drug particles prepared using a controlled precipitation process |
| US20040028746A1 (en) * | 2002-08-06 | 2004-02-12 | Sonke Svenson | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| EP1844765B1 (en) * | 2003-06-13 | 2015-01-21 | Skendi Finance, Ltd. | Slow release estradiol-progesterone formulation |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| CA2532874A1 (en) * | 2003-07-22 | 2005-02-03 | Baxter International Inc. | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| SI1691787T1 (sl) * | 2003-12-04 | 2008-10-31 | Pfizer Prod Inc | Postopek za pripravo farmacevtskih produktov iz več delcev |
| PL1718258T3 (pl) | 2004-02-23 | 2009-08-31 | Euro Celtique Sa | Odporne na nadużywanie transdermalne urządzenie do podawania opioidu |
| RU2008100543A (ru) * | 2005-06-17 | 2009-07-27 | БАСФ Акциенгезельшафт (DE) | Способ получения усилителей эффекта отбеливания |
| WO2009120889A2 (en) * | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| EP2272519A4 (en) * | 2008-04-14 | 2011-04-27 | Posi Visionary Solutions Llp | METHOD AND PHARMACEUTICAL COMPOSITION FOR ACHIEVING THE PLASMA PROGESTERONE MIRRORS NECESSARY FOR VARIOUS THERAPEUTIC INDICATIONS |
| FR2939326B1 (fr) * | 2008-12-10 | 2011-04-01 | Univ Joseph Fourier | Procede et dispositif de controle d'une cristallisation. |
| AU2009352681B2 (en) | 2009-09-17 | 2014-11-20 | Upsher-Smith Laboratories, Llc | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
| UY33103A (es) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico |
| ES2560955T3 (es) * | 2010-03-19 | 2016-02-23 | Daiichi Sankyo Company, Limited | Cristal de derivado de diamina y procedimiento de producción del mismo |
| KR101314126B1 (ko) | 2011-03-11 | 2013-10-04 | 서울대학교산학협력단 | 다면체 형상의 약물 전달 시스템 |
| US9351924B2 (en) | 2011-03-11 | 2016-05-31 | Snu R&Db Foundation | Drug delivery system including laminated structure |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| EA034972B1 (ru) | 2014-04-23 | 2020-04-13 | Инсайт Корпорейшн | 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| ITUB20153652A1 (it) | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| PT3472157T (pt) | 2016-06-20 | 2023-05-30 | Incyte Corp | Formas sólidas cristalinas de um inibidor bet |
| PL236889B1 (pl) * | 2017-10-03 | 2021-02-22 | Univ Warszawski Medyczny | Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie |
| EP3542786A1 (en) * | 2018-03-21 | 2019-09-25 | ITF Research Pharma, S.L.U. | Progesterone intravaginal devices |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2447362A (en) | 1945-11-01 | 1948-08-17 | Rca Corp | Production of crystals |
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| US4230621A (en) * | 1978-05-01 | 1980-10-28 | E. R. Squibb & Sons, Inc. | Steroid derivatives and their use in radioimmunoassays |
| DE2843963A1 (de) * | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin |
| IL63968A (en) | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| JPS5799562A (en) | 1980-12-12 | 1982-06-21 | Nippon Shinyaku Co Ltd | Preparation of microcrystal |
| DE3049196A1 (de) | 1980-12-24 | 1982-07-29 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von granulaten aus organischen in form einer schmelze vorliegenden stoffen |
| US4447426A (en) * | 1982-01-18 | 1984-05-08 | E. R. Squibb & Sons, Inc. | Steroid monohydrates, formulations containing same and method |
| JPS58143832A (ja) | 1982-02-22 | 1983-08-26 | Yoshiaki Kawashima | 結晶性化学物質の球状化再結晶法 |
| DE3213025C2 (de) | 1982-04-02 | 1997-06-12 | Fischer Karl Ind Gmbh | Verfahren zur Nachkondensation von Polykondensaten |
| GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
| JPH0714625B2 (ja) | 1987-03-30 | 1995-02-22 | 呉羽化学工業株式会社 | 高結晶化ポリアリ−レンチオエ−テル成形物 |
| US4897307A (en) | 1987-08-11 | 1990-01-30 | The Dow Chemical Company | Process for the solvent-induced crystallization of amorphous poly(etheretherketone)-type polymers and the article formed thereby |
| WO1989002904A1 (fr) | 1987-09-28 | 1989-04-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Procede de preparation de polycarbonate aromatique cristallise et polycarbonate aromatique cristallise ainsi obtenu |
| US4919899A (en) | 1988-02-29 | 1990-04-24 | Herrmann Frederick T | Crystal growth apparatus |
| YU120988A (en) * | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| IT1230566B (it) * | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| US5360478A (en) | 1989-10-16 | 1994-11-01 | Phasex Corporation | Gas anti-solvent recrystallization process |
| FR2663223B1 (fr) | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
| FR2663224B1 (fr) * | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JPH04305226A (ja) | 1991-01-25 | 1992-10-28 | Senichi Masuda | ガス中窒素酸化物の低減方法 |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| US5391810A (en) | 1991-05-23 | 1995-02-21 | Ajinomoto Co., Inc. | Method of crystallizing α-L-aspartyl-L-phenylalanine methyl ester |
| DE4130173A1 (de) | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
| DE4218929C1 (es) | 1992-06-10 | 1993-09-09 | Deutsche Bundesbahn, Vertreten Durch Das Bundesbahn-Zentralamt Minden (Westf.), 4950 Minden, De | |
| US5290913A (en) | 1992-10-08 | 1994-03-01 | Carrier Vibrating Equipment, Inc. | Method and apparatus for the heat treatment of material |
| US5558678A (en) | 1992-11-13 | 1996-09-24 | Karl Fischer Industrieanlagen Gmbh | Process and apparatus for continuous crystallization of plastic granules |
| US5643595A (en) | 1992-11-24 | 1997-07-01 | Alkermes Controlled Therapeutics Inc. Ii | Growth promoters for animals |
| WO1994020116A1 (en) * | 1993-03-10 | 1994-09-15 | University Of Alabama Research Foundation | Artificial primers for glycogen synthesis |
| US5409605A (en) * | 1993-08-05 | 1995-04-25 | Chemical Lime Company | Apparatus and method for treating waste sludge |
| JPH0757558A (ja) * | 1993-08-09 | 1995-03-03 | Showa Electric Wire & Cable Co Ltd | 耐熱絶縁電線 |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US5849651A (en) * | 1995-06-01 | 1998-12-15 | Kabushiki Kaisha Toshiba | Reversible thermal recording medium |
| JPH0957558A (ja) * | 1995-08-18 | 1997-03-04 | Nabeya Iron & Tool Works Ltd | スライド装置 |
| JPH09227558A (ja) * | 1996-02-28 | 1997-09-02 | Fujisawa Pharmaceut Co Ltd | チアゾール化合物の安定な結晶およびその製造方法 |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| JP2000143832A (ja) | 1998-11-10 | 2000-05-26 | Toppan Printing Co Ltd | 高剛性を有するフィルムまたはシート |
-
1998
- 1998-02-25 US US09/030,388 patent/US6287693B1/en not_active Expired - Lifetime
-
1999
- 1999-02-10 EP EP99902729A patent/EP1056444B1/en not_active Expired - Lifetime
- 1999-02-10 AT AT99902729T patent/ATE345779T1/de active
- 1999-02-10 ID IDW20001723A patent/ID26523A/id unknown
- 1999-02-10 EP EP09156268.6A patent/EP2085075B1/en not_active Expired - Lifetime
- 1999-02-10 ES ES09156268.6T patent/ES2609284T3/es not_active Expired - Lifetime
- 1999-02-10 BR BR9908156-3A patent/BR9908156A/pt not_active Application Discontinuation
- 1999-02-10 NZ NZ505987A patent/NZ505987A/en not_active IP Right Cessation
- 1999-02-10 HU HU0101271A patent/HUP0101271A3/hu unknown
- 1999-02-10 KR KR1020007009352A patent/KR100726315B1/ko not_active Expired - Fee Related
- 1999-02-10 ES ES99902729T patent/ES2275334T3/es not_active Expired - Lifetime
- 1999-02-10 DK DK09156268.6T patent/DK2085075T3/en active
- 1999-02-10 AU AU22936/99A patent/AU747779B2/en not_active Expired
- 1999-02-10 CZ CZ20003047A patent/CZ301042B6/cs not_active IP Right Cessation
- 1999-02-10 DK DK06022834T patent/DK1772141T3/da active
- 1999-02-10 CN CNB998032794A patent/CN1146407C/zh not_active Expired - Fee Related
- 1999-02-10 RU RU2000124327/15A patent/RU2225708C2/ru not_active IP Right Cessation
- 1999-02-10 ZA ZA9901058A patent/ZA991058B/xx unknown
- 1999-02-10 JP JP2000533103A patent/JP4885357B2/ja not_active Expired - Fee Related
- 1999-02-10 PT PT91562686T patent/PT2085075T/pt unknown
- 1999-02-10 CN CNB2004100076469A patent/CN100528140C/zh not_active Expired - Fee Related
- 1999-02-10 DE DE69934099T patent/DE69934099T2/de not_active Expired - Lifetime
- 1999-02-10 TR TR2000/02462T patent/TR200002462T2/xx unknown
- 1999-02-10 ES ES06022834T patent/ES2324366T3/es not_active Expired - Lifetime
- 1999-02-10 EE EEP200000492A patent/EE05019B1/xx unknown
- 1999-02-10 PL PL343170A patent/PL196369B1/pl unknown
- 1999-02-10 EP EP10183811A patent/EP2319497B1/en not_active Expired - Lifetime
- 1999-02-10 IL IL13797099A patent/IL137970A0/xx active IP Right Grant
- 1999-02-10 DK DK99902729T patent/DK1056444T3/da active
- 1999-02-10 CA CA002319176A patent/CA2319176C/en not_active Expired - Fee Related
- 1999-02-10 AT AT06022834T patent/ATE427102T1/de active
- 1999-02-10 EP EP06022834A patent/EP1772141B1/en not_active Expired - Lifetime
- 1999-02-10 WO PCT/IB1999/000233 patent/WO1999043304A1/en not_active Ceased
- 1999-02-10 DE DE69940684T patent/DE69940684D1/de not_active Expired - Lifetime
- 1999-02-12 MY MYPI99000491A patent/MY138375A/en unknown
- 1999-02-17 PE PE1999000141A patent/PE20000393A1/es not_active IP Right Cessation
- 1999-02-23 AR ARP990100728A patent/AR018107A1/es not_active Application Discontinuation
- 1999-02-24 UY UY25404A patent/UY25404A1/es not_active Application Discontinuation
- 1999-03-12 TW TW088103853A patent/TWI256308B/zh not_active IP Right Cessation
- 1999-05-05 SA SA99200098A patent/SA99200098B1/ar unknown
- 1999-10-02 UA UA2000095446A patent/UA73470C2/uk unknown
-
2000
- 2000-07-12 US US09/615,061 patent/US6537580B1/en not_active Expired - Lifetime
- 2000-08-20 IL IL137970A patent/IL137970A/en not_active IP Right Cessation
- 2000-08-24 NO NO20004241A patent/NO331804B1/no not_active IP Right Cessation
-
2001
- 2001-05-23 US US09/862,723 patent/US6528094B1/en not_active Expired - Lifetime
-
2002
- 2002-01-15 US US10/045,148 patent/US6638536B2/en not_active Expired - Lifetime
- 2002-05-29 US US10/156,079 patent/US6663895B2/en not_active Expired - Lifetime
-
2003
- 2003-02-26 US US10/372,897 patent/US7427413B2/en not_active Expired - Fee Related
- 2003-02-26 US US10/373,088 patent/US6737081B2/en not_active Expired - Lifetime
-
2010
- 2010-03-17 AR ARP100100845A patent/AR077168A2/es not_active Application Discontinuation
- 2010-03-17 AR ARP100100844A patent/AR077167A2/es not_active Application Discontinuation
- 2010-12-02 CL CL2010001333A patent/CL2010001333A1/es unknown
-
2011
- 2011-07-22 JP JP2011161017A patent/JP2011241220A/ja not_active Withdrawn
-
2016
- 2016-12-28 CY CY20161101356T patent/CY1118522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077167A2 (es) | Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos | |
| HUP0001547A2 (hu) | Az S-omeprazol új formája | |
| ATE230736T1 (de) | Verfahren zum extrahieren und reinigung von paclitaxel aus natürlicher quelle | |
| DK0624596T3 (da) | Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler | |
| DE3466889D1 (en) | Method for adhering two different surfaces by means of water dispersible polyurethane adhesive compostitions | |
| CO5011099A1 (es) | Formulaciones en polvo en estado cristalino estable | |
| ES2057490T3 (es) | Derivados heterociclicos de acilaminotiazoles, su preparacion y composiciones farmaceuticas que los contienen. | |
| DE3484529D1 (de) | Zielscheibe aus molybdenum mit hoher reinheit und zielscheibe aus molybdenumsilizid mit hoher reinheit fuer lsi-elektroden und verfahren zu deren herstellung. | |
| IT1254619B (it) | Procedimento per la purificazione di acido ftalimmido-perossicaproico (pap) da impurezze di solventi clorurati | |
| ATE192920T1 (de) | Hilfsmittel zum löschmachen von hydrophylen makromolekülen | |
| BRPI0413432A (pt) | método de esterificação de amido | |
| ATE119905T1 (de) | Makrolide antibiotika und verfahren zu deren herstellung. | |
| HUP0000937A2 (hu) | Új zsírsav-származékok | |
| ES8305714A1 (es) | Procedimiento para la produccion de derivados de piperidile-no | |
| ES8206477A1 (es) | Procedimiento para la obtencion de 1,4-dihidropiridinas en- lazadas en c-3. | |
| EP0312248A3 (en) | Acridinium ester labelling and purification of nucleotide probes | |
| IT1165252B (it) | Procedimento di purificazione dell'acido ursodesossicolico attraverso nuovi derivati | |
| BR0011815B1 (pt) | processo para a purificação de poloxámeros que contêm impurezas de aldeìdo. | |
| ES8701725A1 (es) | Procedimiento para la preparacion de 1,4-dihidropiridina-hidroximina. | |
| Howell et al. | Role of microtubules in the intracellular transport of growth hormone | |
| KR920004903A (ko) | 광학상을 형성할 수 있는 전착가능한 포토레지스트 조성물 | |
| ES8600224A1 (es) | Procedimiento de preparacion de nuevos derivados carbamiloxibenzoles | |
| DE60023544D1 (de) | Zusammensetzungen enthaltend eine kombination von defi und modifizierten defi und verfahren zur herstellung | |
| ATE239017T1 (de) | 1,4-dihydropyridin-5-carbonsäureester-derivate und verfahren zu ihrer herstellung | |
| Mendelsohn et al. | The in vitro catabolism of cholesterol. Formation of cholic acid from cholesterol in rat liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |